Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases

被引:401
|
作者
van der Geest, Lydia G. M. [1 ]
Lam-Boer, Jorine't [2 ]
Koopman, Miriam [3 ]
Verhoef, Cees [4 ]
Elferink, Marloes A. G. [1 ]
de Wilt, Johannes H. W. [2 ]
机构
[1] Netherlands Comprehens Canc Org IKNL, NL-3501 DB Utrecht, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Surg, Nijmegen, Netherlands
[3] Univ Utrecht, Dept Med Oncol, Med Ctr, Utrecht, Netherlands
[4] Rotterdam Univ, Med Ctr, Dept Surg, Rotterdam, Netherlands
关键词
Epidemiology; Colorectal cancer; Synchronous metastases; Treatment; Survival; LIVER METASTASES; LUNG METASTASES; COLON-CANCER; MANAGEMENT; FLUOROURACIL; LEUCOVORIN; IRINOTECAN; RESECTION; OXALIPLATIN; IMPROVEMENT;
D O I
10.1007/s10585-015-9719-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to determine trends in incidence, treatment and survival of colorectal cancer (CRC) patients with synchronous metastases (Stage IV) in the Netherlands. This nationwide population-based study included 160,278 patients diagnosed with CRC between 1996 and 2011. We evaluated changes in stage distribution, location of synchronous metastases and treatment in four consecutive periods, using Chi square tests for trend. Median survival in months was determined, using Kaplan-Meier analysis. The proportion of Stage IV CRC patients (n = 33,421) increased from 19 % (1996-1999) to 23 % (2008-2011, p < 0.001). This was predominantly due to a major increase in the incidence of lung metastases (1.7-5.0 % of all CRC patients). During the study period, the primary tumor was resected less often in Stage IV patients (65-46 %) and the use of systemic treatment has increased (29-60 %). Also an increase in metastasectomy was found in patients with one metastatic site, especially in patients with liver-only disease (5-18 %, p < 0.001). Median survival of all Stage IV CRC patients increased from 7 to 12 months. Especially in patients with metastases confined to the liver or lungs this improvement in survival was apparent (9-16 and 12-24 months respectively, both p < 0.001). In the last two decades, more lung metastases were detected and an increasing proportion of Stage IV CRC patients was treated with systemic therapy and/or metastasectomy. Survival of patients has significantly improved. However, the prognosis of Stage IV patients becomes increasingly diverse.
引用
收藏
页码:457 / 465
页数:9
相关论文
共 50 条
  • [31] Treatment outcomes and prognostic factors in patients with colorectal cancer and synchronous lung metastases in the conversion therapy era
    Nozawa, Hiroaki
    Suzuki, Nobumi
    Tsushima, Tatsuya
    Murono, Koji
    Sasaki, Kazuhito
    Emoto, Shigenobu
    Fujishiro, Mitsuhiro
    Sato, Masaaki
    Ishihara, Soichiro
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2025, 40 (01)
  • [32] Insights into synchronous peritoneal metastases from hepatobiliary origin: Incidence, risk factors, treatment, and survival from a nationwide database
    Rijken, Anouk
    Bakkers, Checca
    Klumpen, Heinz-Josef
    van der Geest, Lydia G.
    de Vos-Geelen, Judith
    van Erning, Felice N.
    de Hingh, Ignace H. J. T.
    EJSO, 2023, 49 (08): : 1436 - 1443
  • [33] Outcome of Radical Surgery for Simultaneous Liver and Lung Metastases Synchronous with Primary Colorectal Cancer
    Singhartinger, Franz Xaver
    Varga, Martin
    Jager, Tarkan
    Dinnewitzer, Adam
    Koch, Oliver
    von Rahden, Burkhard H. A.
    Hutter, Jorg
    Emmanuel, Klaus
    INDIAN JOURNAL OF SURGERY, 2022, 84 (01) : 141 - 148
  • [34] Surgical outcomes in patients with hepatic synchronous and metachronous colorectal metastases
    Cossu, Maria Laura
    Ginesu, Giorgio Carlo
    Feo, Claudio Francesco
    Fancellu, Alessandro
    Pinna, Antonio
    Vargiu, Isabel
    Addis, Francesca
    Barmina, Michele
    Sotgiu, Giovanni
    Porcu, Alberto
    ANNALI ITALIANI DI CHIRURGIA, 2017, 88 (06) : 497 - 504
  • [35] Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study
    Bakkers, C.
    van Erning, F. N.
    Rovers, K. P.
    Nienhuijs, S. W.
    Burger, J. W.
    Lemmens, V. E.
    Aalbers, A. G.
    Kok, N. F.
    Boerma, D.
    Brandt, A. R.
    Hemmer, P. H.
    van Grevenstein, W. M.
    de Reuver, P. R.
    Tanis, P. J.
    Tuynman, J. B.
    de Hingh, I. H.
    EJSO, 2020, 46 (10): : 1902 - 1907
  • [36] Prognosis in patients with synchronous colorectal cancer metastases after complete resection of the primary tumor and the metastases
    Stelzner, Sigmar
    Radulova-Mauersberger, Olga
    Zschuppe, Ernst
    Kittner, Thomas
    Abolmaali, Nasreddin
    Puffer, Eric
    Zimmer, Joerg
    Witzigmann, Helmut
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (03) : 438 - 445
  • [37] Hepatic Arterial Infusion with Irinotecan in Patients with Liver Metastases of Colorectal Cancer: Results of an Extended Phase I Study
    Eichler, K.
    Dufas, T.
    Hammerstingl, R.
    Gruber-Rouh, T.
    Vogl, T. J.
    Zangos, S.
    CHEMOTHERAPY, 2013, 59 (01) : 66 - 73
  • [38] An Analysis of Emergency Department Visits and the Survival Rate for Colorectal Cancer Patients: A Nationwide Population-based Study
    Tang, Pei-Ling
    Chang, Hong-Tai
    Cheng, Chin-Chang
    Chen, Hung-Chih
    Kuo, Shyh-Ming
    Hsiao, Kuan-Yin
    Chang, Kuo-Chen
    INTERNAL MEDICINE, 2017, 56 (16) : 2125 - 2132
  • [39] Optimal treatment sequence in colorectal cancer patients with synchronous liver metastases
    Kolbinger, Fiona R.
    Kirchberg, Johanna
    Weitz, Juergen
    Fritzmann, Johannes
    COLOPROCTOLOGY, 2022, 44 (04) : 235 - 243
  • [40] Colorectal Cancer Survival: An Analysis of Patients With Metastatic Disease Synchronous and Metachronous With the Primary Tumor
    Kumar, Rajiv
    Price, Timothy J.
    Beeke, Carol
    Jain, Kunal
    Patel, Gargi
    Padbury, Rob
    Young, Graeme P.
    Roder, David
    Townsend, Amanda
    Bishnoi, Sarwan
    Karapetis, Christos S.
    CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 87 - 93